Fondazione Matilde Tettamanti Menotti De Marchi Onlus Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2017
NCT03389035
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Fondazione Matilde Tettamanti Menotti De Marchi Onlus

Active Ingredients

Drugs in Phase 2 Trials (1)

carcik-cd19 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1